BC Innovations | Jan 21, 2016
Targets & Mechanisms

LRRK2 back on track

The LRRK2 Safety Initiative was put together by The Michael J. Fox Foundation for Parkinson's Research (MJFF) after the Genentech Inc. unit of Roche raised red flags about the target's safety. While the results have...
BC Innovations | Apr 5, 2012
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) ATPase type 13A2 (ATP13A2) In vitro studies suggest upregulating ATP13A2 could help treat PD. In PD patient fibroblasts with mutant ATP13A2 or...
BC Extra | Sep 12, 2006
Clinical News

ATP13A2 gene linked to parkinsonism

Researchers at the University of Cologne and colleagues published in the New England Journal of Medicine that loss-of-function defects in the gene ATP13A2 cause a form of early-onset parkinsonism with dementia known as Kufor-Rakeb syndrome....
Items per page:
1 - 3 of 3